Navigation Links
Rigel's R788 Evaluated in Phase 2 Trial in Multiple Cancers
Date:6/1/2009

and inherently involve significant risks and uncertainties. Rigel's actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the development of R788, including risks related to the timing and success of clinical trials, and potential problems that may arise in the clinical testing and approval process. These and other risk factors are discussed under "Risk Factors" in Rigel's reports filed with the U.S. Securities and Exchange Commission, including its Form 10-Q for the quarter ended March 31, 2008. Rigel undertakes no duty or obligation to update any forward- looking statements contained in this release as a result of new information, future events or changes in its expectations.

    Contact: Raul Rodriguez
    Phone: 650.624.1302
    Email: invrel@rigel.com

    Media Contact: Susan C. Rogers, Alchemy Consulting, Inc.
    Phone: 650.430.3777
    Email: susan@alchemyemail.com


'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Advancements in Integrative Medicine Research to Be Evaluated by Scientists From Leading International Academic Health Centers
2. MDS Announces Strategy to Focus MDS Pharma Services on Early Stage Operations - Discovery Through Phase IIa
3. Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer
4. Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer
5. Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinsons Disease
6. The National Association of Boards of Pharmacy (NABP) Moves to Next Phase of Technician Recognition and Regulation
7. MAP Pharmaceuticals Phase 3 Trial of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints
8. Bioniche Phase III Clinical Trial with Urocidin(TM) Progressing Well
9. National Medical Interpreter Certification Testing Enters Pilot Phase
10. Results of phase III study on Labopharms novel antidepressant published in Psychiatry (Edgemont) Journal
11. Trubion Pharmaceuticals, Inc. to Present Positive Data From a Phase 2b Re-treatment Study of TRU-015 at the 2009 EULAR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... NJ (PRWEB) August 30, 2014 The ... facilities in New Jersey and even in the U.S. ... that takes inches off of patients’ waists with deep-tissue ... cells in small sections, Vanquish is more inclusive to ... Patients lay comfortably under panels about one inch ...
(Date:8/30/2014)... After offering hyperbaric oxygen therapy ... past several years, Dr. Roy Schmidt and the ... a scholarship program for veterans who have been ... held this summer to discuss veterans’ needs ( ... shed light on the large number of veterans ...
(Date:8/30/2014)... Beach, Calif. (PRWEB) August 30, 2014 Insomnia ... Francis helps listeners understand how they unknowingly developed insomnia and ... have restful nights during. Tune in to the show ... The show airs live on August 30, and will ... more information on programming, go to DrCarolFrancisTalkRadio.com. , ...
(Date:8/30/2014)... PA (PRWEB) August 30, 2014 "My ... result of a car accident," said one of two ... muscle strain in her shoulder and neck area. She ... invented reduced pain and pressure, assisting in comfort and ... the patent-pending PILLOW CRADLE to support the head, neck ...
(Date:8/30/2014)... Bringing forth the great opportunities, India's ... Labor Day discount on all SEO services. While working ... services related to internet marketing. Their dedicated team of ... do have a deep understanding for their specialization. This ... and since the inception, they have worked with over ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents, The Plastic Surgery Group 2Health News:Tennessee Hyperbaric Center Offering HBOT Scholarships to Veterans 2Health News:Sleepless Nights, Exhausting Days, Mental Fog – Relief for Insomnia With Clinical Psychologist Dr. Carol Francis 2Health News:Profit By Search Announces Labor Day Discount on SEO Services 2
... difficult for doctors to tell whether a patient with ... inflammation, which can be treated with medicine. A new ... a U-M-led study. Ultrasound elasticity imaging, or UEI, ... inflammation and fibrosis, allowing patients to receive more appropriate ...
... State University of New York has received two grants ... of Health (NIH) to support neuroscience and pediatric pharmacology ... collaborative research network of SUNY,s four academic health centers ... both grants will be headquartered at SUNY Downstate Medical ...
... who experience new onset breast tenderness after starting combination ... cancer compared to women who don,t experience breast tenderness, ... Center has shown. One reason for this may be ... new onset tenderness was much more pronounced after initiation ...
... more effective than the current standard treatment. This is ... treatments, described by Thilo Schwandner and colleagues in the ... Dtsch Arztebl Int 2011; 108[39]: 653-60). In ... The problem is often caused by weakness of the ...
... 1982, alone in a laboratory, chemist Dan Shechtman looked ... He had discovered quasicrystals. But his groundbreaking findings ... years. On October 5, 2011, Shechtman received ... to stand by his research? What drove the men ...
... News) -- Teen drivers are 50 percent more likely to crash ... are after driving for a full year, according to a study ... drivers are nearly twice as likely to crash in the first ... the study found. However, parents can help teens prevent accidents ...
Cached Medicine News:Health News:Imaging technology might help doctors determine best treatment for Crohn's disease patients 2Health News:SUNY receives $4.3 million for research in neuroscience, pediatric pharmacology and vision 2Health News:SUNY receives $4.3 million for research in neuroscience, pediatric pharmacology and vision 3Health News:Breast tenderness in women getting combo hormone therapy associated with increase in breast density 2Health News:Breast tenderness in women getting combo hormone therapy associated with increase in breast density 3Health News:How and why did 2011 Nobel winner Dan Shechtman persist despite rejection? 2Health News:Teen Crash Risk High in First Month of Driving, Study Finds 2
(Date:8/29/2014)... DUBLIN , Aug. 29, 2014 Research ... CNS Disorders Drug Pipeline Insight 2014" report to their ... market in US is one of the largest segments of ... an alarming rate, while the available therapies were unable to ... growth in the market for CNS disorder, especially over the ...
(Date:8/29/2014)... , Aug. 29, 2014  United Therapeutics Corporation (NASDAQ: ... District Court for the District of New ... the company,s case against Sandoz, Inc. regarding United Therapeutics, ... Sheridan ruled that U.S. Patent No. 6,765,117 is ... Sandoz from marketing its generic product until the expiration ...
(Date:8/29/2014)... Pa. , Aug. 29, 2014  Unilife Corporation ... UNS) announced today that it intends to release its ... year ended June 30, 2014 after market trading ends ... has scheduled a conference call for 4:30 p.m. U.S. ... 2014 at 6:30 a.m. AEST), to review the Company,s financial ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
... 2011 ChromaDex® Corp. (OTCBB: CDXC) today announced ... ChromaDex® the exclusive rights to a joint patent ... the method of inducing UDP-glucuronosyltransferase (UGT) activity using ... found in blueberries and demonstrated to have multiple ...
... (Nasdaq: NKTR ) today announced that dosing ... multiple ascending doses of NKTR-181, the company,s novel opioid ... once- or twice-daily oral tablet for the treatment of ... liability and serious central nervous system (CNS) side effects ...
Cached Medicine Technology:ChromaDex®'s Novel Ingredient pTeroPure® to be Studied as Potential Treatment for Fighting Skin Cancers 2ChromaDex®'s Novel Ingredient pTeroPure® to be Studied as Potential Treatment for Fighting Skin Cancers 3Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 2Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 3Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 4Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 5Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 6